A CO2 Supply Crunch Is Threatening a Dry Ice Shortage Just as GLP-1 Shipping Demand Peaks
Dry ice sits at an uncomfortable intersection in 2026: steady underlying demand growth colliding with a genuinely tightening raw material supply chain. The global dry ice market is valued at roughly $1.8 billion in 2026, with total addressable market across 2026-2034 projected to reach approximately $8.47 billion, growing at a 6.8% CAGR driven primarily by pharmaceutical cold chain logistics and e-commerce expansion. But a tight supply of the CO2 used to make dry ice is creating ripple effects across cold-chain packaging supply chains, with industry sources flagging real concern about a potential shortage emerging in 2026.
GLP-1 Drugs Are Reshaping Cold Chain Demand Patterns
Pharma, including GLP-1 drugs, has driven significant recent growth specifically for refrigerated cold-chain solutions, and the shift is granular enough that packaging providers are building dedicated product lines around it: Nordic Cold Chain Solutions introduced Nordic Express Pack specifically for shipping GLP-1 drugs. That matters because it reveals a genuine behavioral distinction in the market: most GLP-1 shipments require refrigeration temperatures of 36 to 46 degrees Fahrenheit rather than the much colder sub-zero range dry ice is built for, meaning the GLP-1 boom is actually driving refrigerated solutions and dry ice demand along two distinct, if related, tracks.
Where Dry Ice Specifically Remains Essential
FDA guidelines for vaccine and cell therapy transport mandate ultra-low temperature maintenance without residual liquids, a requirement only dry ice's sublimation properties can reliably meet
Asia-Pacific is expected to lead the market in 2026, capturing 33.8% of total share, while North America follows at 30.2% and shows the fastest growth among all regions
The narrower dry ice logistics segment specifically, covering cold chain transportation and value-added logistics services, was worth $1.71 billion in 2025 and is projected to reach $3.47 billion by 2035
The market is transitioning toward decentralized, on-demand production, with hospitals and food processing centers increasingly mainstreaming automated on-site dry ice production to reduce reliance on third-party deliveries
On-Site Production Is a Direct Hedge Against the Supply Risk
The cold-chain packaging business depends on differentiated temperature bands, and not every provider is built the same way: Artyc is building what it describes as an on-demand cold chain for healthcare and life sciences, using battery-operated durables that directly cool the payload space via a small compressor rather than relying on dry ice supply at all, a genuinely different technical bet than traditional cold-chain packaging.
No Short-Term Fix Is on the Horizon
Industry sources describe a problematic imbalance in CO2 supply, with no short-term turnaround visible on the horizon, meaning the shortage risk identified for 2026 isn't a brief seasonal blip but a structural supply constraint that cold-chain logistics providers will need to actively manage, whether through alternative cooling technology, on-site production, or long-term supply contracts.
What It Means for the Market
Dry ice's steady demand growth is running directly into a genuine raw material constraint, and the providers best positioned through 2026 are those diversifying away from pure third-party dry ice dependency, whether through on-site production capability or alternative cooling technologies like Artyc's compressor-based approach. The broader lesson for cold-chain logistics buyers: GLP-1 and biologics growth is real, but it's reshaping demand for refrigerated and ultra-cold solutions in distinctly different ways that a single packaging strategy can't address.
Related Reports
Explore our latest coverage of logistics and pharmaceutical supply chain markets:
Evaluating cold chain packaging strategy, supply contracts, or a specific regional logistics investment? Contact us for a customized research report or consulting engagement.
Comments